APA. S. Petrukhin

A. S. Petrukhin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. S. Petrukhin has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The HIHARS-AA phenomenon – a rare state of consciousness induced by hyperventilation, a “mask” of absence epilepsy: literature review with a case report

    by A. A. Nurgaleeva, V. M. Menshenin, Mikhail O. Abramov, A. S. Petrukhin

    HIHARS-AA (hyperventilation-induced high-amplitude rhythmic slowing with altered awareness) is a non-epileptic, age-dependent condition that can coexist with childhood absence epilepsy, clinically indistinguishably mimicking absence seizures. Without video-electroencephalographic monitoring, misinterpretation of this phenomenon leads to diagnostic errors and unnecessary polytherapy, whereas correct verification of the phenomenon allows for optimized treatment and seizure control. The authors present a literature review with a case report.

  • Open Access

    Protocol for developing an Open Base of gRAduated EEG Signals (OBRAS)

    by A. A. Ivanov, D. V. Blinov, K. V. Voronkova, A. S. Petrukhin, O. V. Zaytseva, M. O. Abramov

    Background . Artificial intelligence (AI) systems based on neural networks enabling the automatic analysis of electroencephalography (EEG) examinations, such as detecting episodes of paroxysmal activity are currently being actively developed. Large datasets are required for training neural network algorithms. Objective : To develop a roadmap for the Open Base of Graduated EEG Signals (OBRAS) project, designed to eliminate the shortage of high-quality, annotated EEG recordings suitable for developing and training AI algorithms, as well as for creating educational programs and digital EEG atlases. Material and methods . The project protocol was drafted, which includes the collection of native EEG signals from open sources and from clinical practice of the participants, their deidentification and structured mapping. A two-tier data organization system was proposed: i) primary grouping into folders (e.g., Normal, Epi, NonEpi) and ii) main, flexible classification using a system of tags for age, sex, examination type, pathology, presence of specific EEG patterns, etc. Eligibility criteria and technical requirements for the recordings (format, number of channels, sampling frequency) were defined. Conclusion . The OBRAS project roadmap outlines the protocol, logical sequence of work, annotation methodology, funding model (non-profit partnership), and solutions in the areas of ethics and information security. The creation of such publicly accessible database will accelerate development of AI algorithms for automated EEG analysis. Implementation of the OBRAS project may significantly contribute to developing medical, research, and information technologies in neurophysiology.


  • Open Access

    Hirayama disease and problems of its differential diagnosis with other cervical myelopathies: a case report

    by A. S. Petrukhin, S. A. Malmberg, Y. E. Sadovskaya, Y. B. Pronicheva, Садовская Ю. Е.

    Hirayama disease, or monomelic amyotrophy, is a quite rare type of cervical flexion myelopathy that causes atrophy of the cervical spinal cord. Today, Hirayama disease is an insufficiently studied pathology that requires a thorough examination and differential diagnosis with other variants of myelopathy, which is especially important for excluding such a serious phenomenon as the cervical variant of amyotrophic lateral sclerosis. The presentation of this clinical case makes it possible to increase clinicians’ awareness of Hirayama disease in order to ensure early diagnosis and treatment.

  • Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)

    by V.I. Guzeva, S.I. Kutsev, A.S. Petrukhin, S.O. Ayvazyan, E.D. Belousova, S.G. Burd, I.V. Volkov, O.V. Globa, M.YU. Dorofeeva, N.A. Ermolenko, et al.

    Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.


  • Open Access

    The ILAE classification of epileptic seizures: the 2025 update

    by D. V. Blinov, A. S. Petrukhin, K. V. Voronkova, E. S. Akarachkova, O. V. Kotova, D. I. Korabelnikov, E. I. Rumyantseva, A. N. Mnatsakanyan

    Epilepsy is one of the most common neurological disorders, affecting 51.7 million people worldwide. The International League Against Epilepsy (ILAE) plays a pivotal role in equipping healthcare professionals, patients, government agencies and the general public with the necessary resources to enhance the diagnosis and treatment of epilepsy. In 2025, the ILAE released an updated classification of epileptic seizures, which aimed to address the limitations of previous version and adapt to modern clinical and scientific needs. This publication presents and analyses the ILAE 2025 classification of epileptic seizures, including its development methodology, key changes, and recommendations for clinical application. To develop the document, an ILAE working group was established. This involved conducting a systematic literature review to evaluate the previous version, using a modified Delphi method to reach consensus and implementing a public discussion and peer review process. The updated classification includes four main seizure classes: focal; unknown whether focal or generalized; generalized; and unclassified. Key changes, compared to the previous version include: the removal of the term “onset” from mail seizure class names; introduction of classifiers and descriptors; the term “awareness” has been replaced with “consciousness”; seizures are now described as with or without observable manifestations (basic version) or by the chronological sequence of semiology (expanded version). Epileptic negative myoclonus is recognized as a distinct seizure type. The ILAE 2025 classification of epileptic seizures is a significant step forward in standardizing the diagnosis and treatment of epilepsy, its update helps to improve the quality of medical care and further development of collaboration between epilepsy specialists around the world.


  • Open Access

    Epilepsy and criminal behavior (review of literature)

    by G. M. Musina, K. V. Voronkova, A. S. Petrukhin

    With epilepsy, behavioral disorders are possible, including criminal ones. Criminal incidents can occur in the preictal, interictal, ictal and postictal periods, and may be due to adverse events of anticonvulsants and other factors. The most dangerous postictal behavioral disorder, including in terms of criminal incidents, is postictal psychosis.Often people with epilepsy need experienced neurologists and lawyers to resolve criminal situations. The International League Against Epilepsy recommends criteria for determining whether a particular criminal act committed by a patient with epilepsy is the result of an epileptic seizure.In general, a forensically sound, comprehensive interdisciplinary approach to the diagnosis of criminal behavior in epilepsy is required, which combines neuropsychiatric, neuropsychological and psychophysiological methods, taking into account risk factors and aggravating factors.

  • Open Access

    Terminology of medicines used to control seizure disorders: 2024 ILAE Recommendations and profile of real-world term use

    by D. V. Blinov, A. S. Petrukhin, K. V. Voronkova, E. S. Akarachkova, O. V. Kotova, A. N. Mnatsakanyan, G. P. Kurchatkina

    Background. The International League Against Epilepsy (ILAE) has provided recommendations on the terminology of medicines for control of seizure disorders, which should be adapted into different languages.Objective: to evaluate the usage profile of terms describing the effects of medicines used in patients with epilepsy.Material and methods. The search query analysis systems Google Trends and Yandex Wordstat as well as PubMed/MEDLINE, Google Scholar and eLibrary databases were used to evaluate the general public and professional usage profile, respectively.The following terms in Russian and English were studied: “antiepileptic”, “antiepileptic drug”, “antiseizure”, “antiseizure drug”. In order to ascertain a prevailing opinion within professional and patient communities, a questionnaire survey was conducted on the public online resources of the non-profit partnership “The Association of Epileptologists and Patients” carried out via the cloud-based cross-platform social media as well as instant messaging service Telegram and the social media platform VK.Results. In the English-speaking internet segment, the term “antiepileptic” is used more than 5 times frequently than “antiseizure” by the general public. Conversely, in the Russian-language segment, the term “antiseizure” is almost 2.5 times more common. The term “antiepileptic” is more prevalent in scientific community in both segments. This finding aligns with the profile of terminology usage observed among epileptologists and epilepsy patients. The questionnaire survey results revealed that 56.42% of 179 respondents were in favor of the terms “antiepileptic drug”, “AED” and “antiepileptic therapy”, whereas as few as 17.32% of those endorsed the ILAE-proposed terminology.Conclusion. In light of the established practice of terminology use in both professional scientific community and among practicing epileptologists and epileptic patients, as well as the differences in the semantics of English- and Russian-language terms and the identified lack of precision in the ILAE definition of epilepsy, it can be concluded that for the Russian-speaking population, the terms “antiepileptic drug”, “AED” are more preferable rather than the terms “antiseizure medication”, “ASM”. Additionally, it is preferable to use the terms “convulsive ictus” and “epileptic ictus” due to negative connotation with term “seizure” in Russian. The terms “antiseizure” and “antiepileptic” should not be regarded as mutually exclusive in the context of treatment that has a direct impact on epilepsy course. Finally, it is necessary to further refine epilepsy definition and classification.


  • The role of the phenosanic acid in the combined treatment of patients with epilepsy

    by K.V. Voronkova, A.M. Alieva, I.G. Nikitin, G.M. Musina, E.V. Surskaya, O.S. Zaitseva, N.G. Mashkevich, L.V. Gomonova, A.S. Petrukhin

    Epilepsy is one of the most studied chronic neurological disorders in the world. Despite significant progress in epilepsy research, some patients continue to experience recurrent seizures. It has been proven that oxidative stress plays an important role in epilepsy. Targeting oxidative stress may provide a novel therapeutic intervention to attenuate epileptogenesis as well as cognitive and psychiatric impairment in patients with epilepsy. One of the promising directions in the search for new strategies for the treatment of epilepsy is the combined use of antiepileptic drugs with antioxidants that affect the pathogenetic links of this disease. The new Russian antiepileptic drug fenosanoic acid (Dibufelon) has an anticonvulsant effect due to the inhibition of lipid peroxidation of brain cells and the reconstruction of cell membranes. This mechanism of action also paves the way for an increase in the effectiveness of co-administered drugs with phenosanoic acid. The effect of the drug on the cognitive and mental functions of patients, the regression of asthenia phenomena is also observed. The clinical efficacy and safety of the combination of this drug with other antiepileptic drugs in epilepsy has been demonstrated in experimental and clinical studies.


  • Encephalopathy GNAO1

    by M.YU. Bobylova, I.V. Volkov, E.V. Gumennik, O.A. Rachmanina, M.O. Abramov, O.K. Volkova, T.S. Bayborina, A.S. Petrukhin

    РЕЗЮМЕ ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить клиническую картину всех обнаруженных в Российской Федерации на момент исследования пациентов с энцефалопатией GNAO1, редким аутосомно-доминантным заболеванием, связанным с мутацией гена GNAO1. МАТЕРИАЛ И МЕТОДЫ Публикация является результатом мультицентрового исследования, объединившим данные эпилептологических центров Москвы, Новосибирска, Санкт-Петербурга, Нижнего Новгорода, Тюмени. Включены 9 пациентов в возрасте от 2 до 19 лет с 4 мутациями. Соотношение пациентов мужского и женского полов 5:4. РЕЗУЛЬТАТЫ У 8 пациентов (5 — с мутацией c.607G>A (p.Gly203Arg), 1 — c.155A>G (Gln52Arg), 1 — c.485G>A (p.Arg162Gln)) отмечался вариант эпилептической энцефалопатии, энцефалопатии развития, у 1 пациентки — ДЦП-подобный вариант с наличием торсионной дистонии без клинических проявлений синдрома GNAO1 эпилепсии (мутация c.713A>G (p.Asp238Gly)). Эпилептические приступы у 8 детей с эпилептической энцефалопатией GNAO1 в 100% дебютировали на 1-м месяце жизни, став самым ранним симптомом заболевания. Задержка двигательного развития отмечалась в 100% случаев. Психическое развитие не пострадало только в случае дистонического варианта. Гиперкинезы в виде дистонии, хореоатетоза и баллизма присоединялись позже — с 2 до 8 мес. Они протекали более тяжело, чем эпилепсия, и составляли ядро клинической картины у всех детей. У 4 пациентов с мутацией c.607G>A (p.Gly203Arg) развивались повторные «дистонические бури», которые были резистентны к большинству препаратов. ЗАКЛЮЧЕНИЕ Эпилепсия при GNAO1 трудно поддается лечению, но можно достичь временной или полной ремиссии. Эффективные медикаментозные стратегии для лечения гиперкинезов в настоящее время не разработаны. Желательно расширение показаний для хирургической терапии гиперкинезов при данном синдроме.